Myriad Genetics (MYGN) CFO granted 206,186 RSUs, 4,752 shares withheld

Rhea-AI Filing Summary

Myriad Genetics Chief Financial Officer Benjamin Richard Wheeler reported equity compensation and related tax withholding transactions in company common stock. On March 12, 2026, he received 206,186 time-based restricted stock units, each representing one future share, vesting in three equal annual installments beginning on the first anniversary of the grant date.

Between March 13 and March 15, 2026, a total of 4,752 shares of common stock were withheld by the company to cover tax obligations tied to vesting of previously granted time-based and performance-based restricted stock units. These are tax-withholding dispositions rather than open-market sales. After these transactions, Wheeler directly holds 299,058 shares of Myriad Genetics common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wheeler Benjamin Richard

(Last) (First) (Middle)

322 NORTH 2200 WEST

(Street)

SALT LAKE CITY UT 84116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MYRIAD GENETICS INC [ MYGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/12/2026		A		206,186(1)	A	$0	303,810	D
Common Stock	03/13/2026		F		586(2)	D	$4.66	303,224	D
Common Stock	03/14/2026		F		1,097(2)	D	$4.66	302,127	D
Common Stock	03/15/2026		F		877(2)	D	$4.66	301,250	D
Common Stock	03/15/2026		F		2,192(3)	D	$4.66	299,058	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Consists of time-based restricted stock units granted pursuant to the Issuer's 2017 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.

2. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of Issuer's Common Stock on March 13, 2026.

3. Represents shares of Common Stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units previously granted to the Reporting Person. The number of shares withheld was determined based on the closing price of the Issuer's Common Stock on March 13, 2026.

Remarks:

	By: Justin Hunter For: Benjamin R. Wheeler	03/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Myriad Genetics (MYGN) report for its CFO?

Myriad Genetics reported that CFO Benjamin Richard Wheeler received 206,186 restricted stock units and had 4,752 shares withheld for taxes. All dispositions were tax-withholding transactions related to vesting, with no open-market purchases or sales disclosed in this filing.

How many restricted stock units did the Myriad Genetics (MYGN) CFO receive?

The CFO received 206,186 time-based restricted stock units in March 2026. Each unit represents a contingent right to one Myriad Genetics common share, vesting in three equal annual installments starting on the first anniversary of the grant date.

How do the Myriad Genetics (MYGN) CFO’s restricted stock units vest?

The restricted stock units vest in three equal annual installments beginning on the first anniversary of the March 12, 2026 grant date. Each vested unit converts into one share of Myriad Genetics common stock as the vesting conditions are satisfied over time.

Were Myriad Genetics (MYGN) shares sold on the market in this Form 4?

No open-market share sales were reported. The filing shows 4,752 shares of common stock withheld by the issuer solely to satisfy tax obligations from vesting of previously granted time-based and performance-based restricted stock units to the CFO.

How many Myriad Genetics (MYGN) shares does the CFO hold after these transactions?

After the reported grant and tax-withholding transactions, CFO Benjamin Richard Wheeler directly holds 299,058 shares of Myriad Genetics common stock. This represents his post-transaction direct ownership, as disclosed in the Form 4’s share balance fields.

What price was used for Myriad Genetics (MYGN) tax withholding in the CFO’s Form 4?

The number of shares withheld for taxes was based on the closing price of Myriad Genetics common stock on March 13, 2026. Each tax-withholding transaction in the filing uses a price field of $4.66 per share to determine shares withheld.